Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Randomized, Placebo Controlled, Double-blind, Double-dummy Three-way Cross Over Trial to Investigate the Effect of BI 409306, BI 425809 and Lamotrigine on Ketamine-induced Cognitive Deficits in Healthy Male Subjects

To see complete record on, please visit this link

Id: NCT04602221

Organisation Name: Boehringer Ingelheim

Overal Status: Completed

Start Date: December 1, 2020

Last Update: August 22, 2022

Lead Sponsor: Boehringer Ingelheim

Brief Summary: The main objective of this trail is to investigate if and to what extent BI 409306, BI 425809 and lamotrigine attenuate ketamine induced cognitive deficits.

  • Healthy

Total execution time in seconds: 0.20056796073914